new BindingDB logo
myBDB logout

36 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
2909730 10 Flavones. 2. Synthesis and structure-activity relationship of flavodilol and its analogues, a novel class of antihypertensive agents with catecholamine depleting properties.EBI Pennwalt Corporation
2887658 5 Carbostyril derivatives having potent beta-adrenergic agonist properties.EBI TBA
2883317 6 Flavones. 1. Synthesis and antihypertensive activity of (3-phenylflavonoxy)propanolamines without beta-adrenoceptor antagonism.EBI TBA
2882025 20 Affinity labels for beta-adrenoceptors: preparation and properties of alkylating beta-blockers derived from indole.EBI TBA
2866247 20 Alkylating beta-blockers: activity of isomeric bromoacetyl alprenolol menthanes.EBI TBA
6131128 30 beta-Adrenergic antagonists with multiple pharmacophores: persistent blockade of receptors.EBI TBA
6124637 18 Syntheses and adrenergic agonist properties of ring-fluorinated isoproterenols.EBI TBA
7328588 9 Synthesis and adrenoceptor affinity of some highly polar beta-substituted catecholamines.EBI TBA
6120233 43 beta-Adrenergic blocking agents. alpha- and gamma-methyl(aryloxy)propanolamines.EBI TBA
6248642 38 Mammalian alkaloids. 8. Synthesis and biological effects of tetrahydropapaveroline related 1-benzyltetrahydroisoquinolines.EBI TBA
26709102 142 Discovery of Vibegron: A Potent and Selective▀3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.EBI Merck Research Laboratories
26125514 40 Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human▀3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.EBI Asahi Kasei Pharma Corporation
11311067 38 Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.EBI Kissei Pharmaceutical Company Ltd.
24900353 6 Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.EBI TBA
7562902 114 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.EBI SmithKline Beecham Pharmaceuticals
8254623 54 Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.EBI National Institute of Diabetes and Digestive and Kidney Diseases
1573641 60 SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype.EBI Searle Research and Development
1361578 99 Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.EBI Bristol-Myers Squibb Co.
2539480 50 Design and synthesis of propranolol analogues as serotonergic agents.EBI Virginia Commonwealth University
2845082 35 Syntheses and adrenergic activities of ring-fluorinated epinephrines.EBI National Institute of Diabetes
6134833 91 Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans.EBI TBA
20812727 157 Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.EBI National Institute of Mental Health
 7 SYNTHESIS AND BIOLOGICAL EVALUATION OF A FLUORINATED ANALOG OF THE β-ADRENERGIC BLOCKING AGENT, METOPROLOLEBI TBA
 3 Asymmetric synthesis of FR165914: A novel β3-adrenergic agonist with a benzocycloheptene structureEBI TBA
17911024 37 Potent oxindole based human beta3 adrenergic receptor agonists.EBI Lilly Research Laboratories
17632003 55 Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.EBI Pfizer Global Research and Development
16931005 21 Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.EBI Lilly Research Laboratories
8496920 14 (S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.EBI Wyeth Research (UK)
8411007 392 Chemistry, binding affinities, and behavioral properties of a new class of"antineophobic" mitochondrial DBI receptor complex (mDRC) ligands.EBI Mayo Foundation for Medical Education and Research
8410999 81 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.EBI Lilly Research Laboratories
8246239 84 Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.EBI Solvay Duphar B.V.
3746815 15 In vitro labeling of serotonin-S2 receptors: synthesis and binding characteristics of [3H]-7-aminoketanserin.EBI TBA
1672155 14 Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.EBI National Institute of Diabetes
1652026 43 Analogues of the 5-HT1A serotonin antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine with reduced alpha 1-adrenergic affinity.EBI Virginia Commonwealth University
1354264 19 Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.EBI American Cyanamid Company